Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI resistant renal cancer

PURPOSE: VEGFR2 tyrosine kinase inhibition (TKI) is a valuable treatment approach for patients with metastatic RCC. However, resistance to treatment is inevitable. Identification of novel targets could lead to better treatment for both patients with TKI naïve or resistant RCC. EXPERIMENTAL DESIGN: I...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Zhang, Liang, Wang, Xiaoen, Bullock, Andrea J., Callea, Marcella, Shah, Harleen, Song, Jiaxi, Moreno, Kelli, Visentin, Barbara, Deutschman, Douglas, Alsop, David C., Atkins, Michael B., Mier, James W., Signoretti, Sabina, Bhasin, Manoj, Sabbadini, Roger A., Bhatt, Rupal S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2015
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4419371/
https://ncbi.nlm.nih.gov/pubmed/25589614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2031
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia